Tech
Opyl (ASX: OPL) are a Melbourne based company with client service and development teams in both Australia and the US.
Opyl provides biopharma and health organisations access to emerging AI-assisted technologies and professional guidance to understand and improve healthcare design, development and delivery.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Opyl tips growing demand for its clinical trial recruitment platform post-lockdown
Tech
Bargain Barrel: Could one of these sub-$20m market cap tech stocks be a diamond in the rough?
News
Closing Bell: ASX goes green to start the week
Health & Biotech
Opyl is ready to scale up AI platform Opin after delivering full-year revenue growth
Health & Biotech
Stock Insiders Podcast: Investors eye Opyl’s strong revenues and expanded offering following launch of ‘Opin’ clinical trial recruitment platform
News
ASX Small Cap Lunch Wrap: Who’s following in the footsteps of giants today?
Experts
Opentrader’s Kieran Neeson: Some thoughts on APT-Square and ASX stock picks for the back end of 2021
Health & Biotech
Opyl shares bounce on Q4 trading update with key revenue drivers in place for FY22
Health & Biotech
Opyl reaches key milestone for its clinical trial recruitment platform Opin, shares jump
Stockhead TV
Healthcare: Clinical trial inefficiencies and the role of artificial intelligence
Health & Biotech
Introducing Opin, Opyl’s AI platform that recruits clinical trial patients from around the world
Health & Biotech
Opyl makes a strategic board recruitment as it looks to commercialise its product offerings
News
Last Orders: ASX slides again – falls below 7,000 mark
Tech
Opyl completes major milestone on clinical trials platform, on track for go-live in May
Tech
Opyl taking two steps to revolutionise clinical trials this year
Tech
Opyl delivers maiden profit as first-half revenue jumps 33%
Experts
